
ANG Lifesciences India Ltd Downgraded to Strong Sell Amid Weak Financials and Mixed Technicals
2026-10-26 08:21:19ANG Lifesciences India Ltd has seen its investment rating downgraded from Sell to Strong Sell as of 23 Oct 2026, reflecting deteriorating financial fundamentals and a complex technical outlook. Despite some mildly bullish technical signals, the company’s weak profitability, high debt burden, and negative operating performance have weighed heavily on investor sentiment, leading to a significant reassessment of its prospects.
Read More
ANG Lifesciences India Ltd Upgraded to Sell Amid Mixed Technical and Financial Signals
2026-10-22 08:41:24ANG Lifesciences India Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 21 Oct 2026, driven primarily by improved technical indicators despite ongoing financial challenges. The micro-cap pharmaceutical company’s Mojo Score rose to 31.0, reflecting a shift in market sentiment, although fundamental weaknesses and valuation concerns persist.
Read More
ANG Lifesciences India Ltd is Rated Strong Sell
2026-10-21 10:10:56ANG Lifesciences India Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 22 September 2026, reflecting a reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed below are based on the company’s current position as of 21 October 2026, providing investors with the latest comprehensive view.
Read More
ANG Lifesciences India Ltd is Rated Strong Sell
2026-10-06 10:11:00ANG Lifesciences India Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 22 September 2026, reflecting a reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed here are current as of 06 October 2026, providing investors with the latest perspective on the company’s position.
Read More
ANG Lifesciences India Ltd Downgraded to Strong Sell Amid Weak Financials and Mixed Technicals
2026-09-23 08:21:50ANG Lifesciences India Ltd has seen its investment rating downgraded from Sell to Strong Sell as of 22 September 2026, reflecting a complex interplay of deteriorating financial fundamentals and mixed technical signals. Despite some positive price momentum over recent months, the company’s weak profitability, high leverage, and subdued long-term prospects have compelled analysts to revise their stance, signalling caution for investors in this micro-cap pharmaceutical stock.
Read More
ANG Lifesciences India Ltd Upgraded to Sell on Technical Improvements Despite Weak Fundamentals
2026-09-18 08:15:20ANG Lifesciences India Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 17 Sep 2026, driven primarily by improved technical indicators. However, the company’s financial health and valuation metrics remain weak, reflecting ongoing operational challenges and elevated risk for investors.
Read MoreAnnouncement under Regulation 30 (LODR)-Change in Management
18-Nov-2026 | Source : BSECessation of Independent Director upon completion of tenure.
Announcement under Regulation 30 (LODR)-Change in Management
14-Nov-2026 | Source : BSEAppointment of Mrs. Preeti Sarin as Additional Independent Director of the Company
Financial Results For The Quarter And Half Year Ended 30.09.2026.
14-Nov-2026 | Source : BSEFinancial Results for the quarter and half year ended 30.09.2026.
Corporate Actions
No Upcoming Board Meetings
ANG Lifesciences India Ltd has declared 10% dividend, ex-date: 02 Nov 21
No Splits history available
ANG Lifesciences India Ltd has announced 1:4 bonus issue, ex-date: 13 Jul 22
No Rights history available